5.62

0.88% -0.05

After Hours: 5.60 -0.02 -0.36%

Ars Pharmaceuticals Inc (SPRY)

Overview News Price History Option Chain Financials Discussions Forecast

Ars Pharmaceuticals Inc stock is traded at $5.62, with a volume of 849.46K. It is down -0.88% in the last 24 hours and up +5.64% over the past month. ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Previous Close:

$5.67

Open:

$5.6

24h Volume:

849.46K

Relative Volume:

0.42

Market Cap:

$558.89M

Revenue:

$98.99M

Net Income/Loss:

$-197.98M

P/E Ratio:

-2.8076

EPS:

-2.0017

Net Cash Flow:

$-175.32M

1W Performance:

-4.58%

1M Performance:

+5.64%

6M Performance:

-37.83%

1Y Performance:

-47.43%

1-Day Range:

$5.54

$5.70

1-Week Range:

$5.54

$6.09

52-Week Range:

$4.9102

$13.15

Ars Pharmaceuticals Inc Stock (SPRY) Company Profile

Name

Ars Pharmaceuticals Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

858-771-9307

Address

11682 EL CAMINO REAL, SUITE 300, SAN DIEGO

Employee

159

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

SPRY's Discussions on Twitter

Compare SPRY vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SPRY Ars Pharmaceuticals Inc	5.62	547.46M	98.99M	-197.98M	-175.32M	-2.0017
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-09-26	Initiated	Northland Capital	Outperform
Nov-04-25	Resumed	Roth Capital	Buy
Sep-04-25	Initiated	Roth Capital	Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Feb-10-25	Initiated	Oppenheimer	Outperform
Aug-20-24	Initiated	Cantor Fitzgerald	Overweight
Aug-13-24	Upgrade	Raymond James	Outperform → Strong Buy
Aug-12-24	Reiterated	Leerink Partners	Outperform
Jul-25-24	Initiated	Raymond James	Outperform
Mar-05-24	Upgrade	Leerink Partners	Market Perform → Outperform
Feb-20-24	Upgrade	William Blair	Mkt Perform → Outperform
Sep-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Jan-31-23	Initiated	Wedbush	Outperform
Jan-03-23	Initiated	William Blair	Outperform
Dec-13-22	Initiated	SVB Leerink	Outperform

View All

Ars Pharmaceuticals Inc Stock (SPRY) Latest News

Aug 21, 2026

ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share - Yahoo Finance

Aug 21, 2026

SPRY Investors Have Rights – If You Lost Money Investing in - GlobeNewswire

Aug 21, 2026